

Commercializing University Results

Robert A. Lodder, Ph.D.

Professor, University of Kentucky

President, Spherix, Inc.



<http://www.pharm.uky.edu/>

FDA Granted Market Clearance for the LipiScan™ Coronary Imaging System – April 29, 2008

InfraReDx



InfraReDx is dedicated to improving Health Care through the application of Photonics to Medicine.

Corporate Introduction


Technology Development

Vulnerable Plaque

Meet InfraReDx - company profile, employment opportunities, and [more](#).

[click here](#) for information on InfraReDx Technology Development.

Learn more about this disease that is now suspected to cause the majority of heart attacks.



Company Profile Vulnerable Plaque Technology Development Career Opportunities Site Map

Lead VC: Sanderling Biomedical \$56M



Prescient®

pre•cient \presh-ənt\ adj: knowing beforehand

OUR COMPANY OUR PRODUCTS VULNERABLE PLAQUE INVESTOR RELATIONS

Prevent Heart Attacks with Vulnerable Plaque Technology

... what is vulnerable plaque?


...who is vulnerable?



Introduction

New Technology
for Detection of the
Vulnerable Plaque

Cause of
Heart Attack



Plaque
Detection



Optiographic
Catheter™



HOME SITE MAP PRIVACY STATEMENT LEGAL STATEMENT CONTACT PRESCENT MEDICAL

Lead VC: Spencer Trask

\$27M + Series B



NASDAQ: SPEX



► Government ► Healthcare ► Reservations ► Business Solutions ► BioSpherix

Contact Centers,
e-Government,
IT Services,
Contract Vehicles

Contact Centers,
Clinical Trial Support,
Withdrawal Support

Camp reservations,
Tour tickets,
Inventory
Management,
Enterprise Solutions

IT Services,
e-Business,
Knowledge
management

Naturlose,
Mars Research,
Purchase
Carbohydrates

- OVERVIEW
- PRESS RELEASES
- ANNUAL REPORT
- CAREERS
- CONTACT US
- SEC FILING

► OUR HOT SPOTS





► HEADLINES

- TAGATOSE TAKES MAJOR STEP TOWARD APPROVAL IN EUROPE
- SPHERIX EXPANDS CALL CENTER FOR HURRICANE RELIEF EFFORT
- SPHERIX'S STOCKHOLDERS' EQUITY BACK ABOVE \$10 MILLION
- SPHERIX ANNOUNCES SECOND QUARTER GROWTH
- WHAT ARE MARTIANS LIKE?


2007 Annual Sales \$24M, 600+ employees, Public Float (12 million sh)

D-Tagatose Mechanisms of Action in Digestive Tract



Currently in Phase III clinical trials at sites across the US

D-Tagatose Mechanisms of Action in Liver



The net effects of the regulation of these enzymes are to increase glycogen synthesis, and to decrease glycogen utilization.

Phase 2 Dose Ranging Current Enrollment

- **38 patients randomized (23 at the time of the last board meeting)**
- **US-based study**
- **Slight delay reported**
- **Complete before the phase III**
- **Enrollment final Q2 of 2009**

Status of Phase III

- **Global enrollment goal 500 patients randomized by March 31, 2009**
 - 250 United States yielding 150 completers
 - 250 India yielding 180 completers
 - 330 Completers between 2 countries
- **Current Enrollment**
 - Nearly 400 patients screened
 - 169 randomized (104 currently enrolled)
 - 65 dropouts/early terminations
 - Approx 30 patients in the lead in period
 - 200 screen fails

India Timeline

- **Goals**
 - 25 sites/250 patients by March 31, 2009
 - 180 completers
- **Work has begun**
 - Site identification and qualification visits are occurring
 - Regulatory filing to occur this week
 - First patient screened October 31, 2008

Interface Issues

Grants don't scale

Departmental / disciplinary barriers

Interest in entrepreneurship

Accounting, SOX

TTO time constant

Flattening relationship to “bypassing”